FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mineo Takei

Research Profile

Living Beings

Chemicals & Drugs

Concepts & Ideas

Drug Dose Response Relationship

Anatomy

Disorders

Animal Disease Models

Co-author Network

Publications

TOP 3
Kazuyoshi Yoshii; Junko Hasegawa; Masamichi Hirayama; Yukinori Mera; Toshifumi Nakamura; Mineo Takei; Ryoko Toda; Yoshihiro Kawabata
Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach.
Yuki Orikawa; Hiroki Kato; Koichi Seto; Nobuyoshi Kobayashi; Koji Yoshinaga; Hiroki Hamano; Yuko Hori; Tim Meyer; Mineo Takei
Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.
Koji Yoshinaga; Takayuki Horii; Hiroki Hamano; Runa Eta; Tomoko Ozaki; Yuki Orikawa; Kazuyoshi Yoshii; Yoshihiro Kawabata; Yuko Hori; Koichi Seto; Mineo Takei; Yasushi Kuraishi
Pharmacological evaluation of analgesic effects of the cholecystokinin2 receptor antagonist Z-360 in mouse models of formalin- and cancer-induced pain.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mineo Takei (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Kazuyoshi Yoshii; Junko Hasegawa; Masamichi Hirayama; Yukinori Mera; Toshifumi Nakamura; Mineo Takei; Ryoko Toda; Yoshihiro Kawabata
Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach.
Journal of pharmaceutical sciences 2011;100(11):4965-73.
2010: Yuki Orikawa; Hiroki Kato; Koichi Seto; Nobuyoshi Kobayashi; Koji Yoshinaga; Hiroki Hamano; Yuko Hori; Tim Meyer; Mineo Takei
Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.
Molecular pain 2010;6():72.
2010: Koji Yoshinaga; Takayuki Horii; Hiroki Hamano; Runa Eta; Tomoko Ozaki; Yuki Orikawa; Kazuyoshi Yoshii; Yoshihiro Kawabata; Yuko Hori; Koichi Seto; Mineo Takei; Yasushi Kuraishi
Pharmacological evaluation of analgesic effects of the cholecystokinin2 receptor antagonist Z-360 in mouse models of formalin- and cancer-induced pain.
Biological & pharmaceutical bulletin 2010;33(2):244-8.
2010: Nobuyoshi Kobayashi; Koichi Seto; Yuki Orikawa; Hiroki Hamano; Koji Yoshinaga; Mineo Takei
Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells.
Biological & pharmaceutical bulletin 2010;33(2):216-22.
2009: Hiroki Hamano; Koji Yoshinaga; Takao Tanaka; Runa Eta; Takayuki Horii; Yoshihiro Kawabata; Shigeru FURUTA; Mineo Takei
Polaprezinc, a zinc compound, is distributed to the lingual epithelium and increases its zinc concentration in zinc-deficient rats.
Life sciences 2009;85(21-22):759-64.
2008: Daisuke Kawasaki; Yutaka Emori; Runa Eta; Yuka Iino; Hiroki Hamano; Koji Yoshinaga; Takao Tanaka; Mineo Takei; Susan A Watson
Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
Cancer chemotherapy and pharmacology 2008;61(5):883-92.
2006: Hiroki Hamano; Koji Yoshinaga; Runa Eta; Yutaka Emori; Daisuke Kawasaki; Yuka Iino; Miwa Sawada; Hiroyuki Kuroda; Mineo Takei
Effect of polaprezinc on taste disorders in zinc-deficient rats.
BioFactors (Oxford, England) 2006;28(3-4):185-93.
2004: Yutaka Emori; Tamako Ikeda; Takashi Ohashi; Takao Masuda; Tadashi Kurimoto; Mineo Takei; Mari Kannagi
Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages.
The Journal of general virology 2004;85(Pt 9):2603-13.
2004: Yoshihiro Kawabata; Emiko Kamada; Shigeru FURUTA; Mineo Takei; Tadashi Kurimoto; Kazuho Okudaira; Ryuichiro Nishigaki
ATP-dependent transport of a novel thromboxane A2 receptor antagonist, [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) and its xenobiotic taurine conjugate (Z-335-Tau) by rat bile canalicular membrane vesicles.
Pharmaceutical research 2004;21(3):467-75.
2004: Hideki Oka; Hidetaka Sasaki; Yumiko Shiraishi; Yutaka Emori; Koji Yoshinaga; Mineo Takei
Z-100, an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, augments anti-tumor activities of X-ray irradiation against B16 melanoma in association with the improvement of type 1T cell responses.
Biological & pharmaceutical bulletin 2004;27(1):82-8.
2003: Hideki Oka; Yumiko Shiraishi; Hidetaka Sasaki; Koji Yoshinaga; Yutaka Emori; Mineo Takei
Antimetastatic effect of an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, Z-100, through the production of interleukin-12.
Biological & pharmaceutical bulletin 2003;26(9):1336-41.
2001: Shigeru FURUTA; Y Fukuda; Tohru Sugimoto; H Miyahara; Emiko Kamada; H Sano; Yasuhisa Fukuta; Mineo Takei; Tadashi Kurimoto
Pharmacodynamic analysis of steroid 5alpha-reductase inhibitory actions of Z-350 in rat prostate.
European journal of pharmacology 2001;426(1-2):105-11.
2001: Y Fukuda; Yasuhisa Fukuta; R Higashino; K Yoshida; M Ogishima; Mineo Takei; Tadashi Kurimoto
Hormonal effects of Z-350, possessing steroid 5alpha-reductase inhibitory and alpha1-adrenoceptor antagonistic actions, in the rat.
Japanese journal of pharmacology 2001;86(3):323-8.
1999: T Tanaka; Yasuhisa Fukuta; Y Fukuda; R Higashino; S Ito; Mineo Takei; H Tamaki; Tadashi Kurimoto; Y Suzuki
Z-335, a thromboxane A2 receptor antagonist, suppresses the progression of arachidonic acid-induced hind limb gangrene in rats.
Biological & pharmaceutical bulletin 1999;22(12):1382-4.
1999: Y Fukuda; M Sawata; M Washizuka; R Higashino; Yasuhisa Fukuta; Y Tanaka; Mineo Takei
[Effect of liver hydrolysate on hepatic proliferation in regenerating rat liver].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 1999;114(4):233-8.
1999: Yasuhisa Fukuta; Y Fukuda; R Higashino; K Yoshida; M Ogishima; H Tamaki; Mineo Takei
Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo.
The Journal of pharmacology and experimental therapeutics 1999;290(3):1013-8.
1999: H Sato; O Kitagawa; Y Aida; J Chikazawa; Tadashi Kurimoto; Mineo Takei; Yasuhisa Fukuta; K Yoshida
Dual-acting agents with alpha1-adrenoceptor antagonistic and steroid 5alpha-reductase inhibitory activities. Synthesis and evaluation of arylpiperazine derivatives.
Bioorganic & medicinal chemistry letters 1999;9(11):1553-8.
1999: Y Fukuda; Yasuhisa Fukuta; R Higashino; M Ogishima; K Yoshida; H Tamaki; Mineo Takei
Z-350, a new chimera compound possessing alpha1-adrenoceptor antagonistic and steroid 5alpha-reductase inhibitory actions.
Naunyn-Schmiedeberg's archives of pharmacology 1999;359(6):433-8.
1999: T Tanaka; Mineo Takei; Yasuhisa Fukuta; R Higashino; Y Fukuda; Y Nomura; S Ito; H Tamaki; Tadashi Kurimoto; Y Suzuki
Arachidonic acid-induced hind limb gangrene: a new experimental rat model of peripheral vascular disease.
Biological & pharmaceutical bulletin 1999;22(3):257-60.
1998: T Tanaka; Yasuhisa Fukuta; R Higashino; R Sato; Y Nomura; Y Fukuda; S Ito; Mineo Takei; Tadashi Kurimoto; H Tamaki
Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist.
European journal of pharmacology 1998;357(1):53-60.
1998: T Tanaka; S Ito; R Higashino; Yasuhisa Fukuta; Y Fukuda; Mineo Takei; Tadashi Kurimoto; H Tamaki
A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time.
Thrombosis research 1998;91(5):229-35.
1995: S Ito; R Higashino; T Tanaka; Mineo Takei; Tadashi Kurimoto; K Matsuda
[Effect of efonidipine hydrochloride (NZ-105) on modification of low density lipoprotein induced by rat cultured endothelial cells].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 1995;106(4):263-70.
1995: T Matsumura; H Furuichi; J Izumi; H Suda; S Ito; Mineo Takei; N Nishi; T Mori; Y Tanaka; Tadashi Kurimoto
[Effect of efonidipine hydrochloride, a calcium channel blocker, on the experimental cerebral ischemia/anoxia].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 1995;105(6):437-46.
1993: T Matsumura; H Furuichi; J Izumi; Y Kamatsuka; Mineo Takei; N Nakata; S Ito; H Suda; K Kizaki; Tadashi Kurimoto
[Effects of NC-1100, a calcium channel blocker, on experimental cerebral ischemia/anoxia in rodents].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 1993;101(3):177-86.